April 2018

Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018

Press - old WP ej via Cision, Pressrelease / By

Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related genes in tumours with progression-free survival (PFS) in metastasizing colorectal cancer (mCRC) patients, treated with 5-FU/folate based therapy has been accepted for presentation at ASCO 2018, taking place 1-5th of June in Chicago, USA. The accepted abstract describes a gene …

Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018 Read More »

Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018

Pressmeddelande / By

Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related genes in tumours with progression-free survival (PFS) in metastasizing colorectal cancer (mCRC) patients, treated with 5-FU/folate based therapy has been accepted for presentation at ASCO 2018, taking place 1-5th of June in Chicago, USA. The accepted abstract describes a gene expression study conducted by academic researchers collaborating with Isofol Medical.

Invitation to a specialist investor event focusing on late-stage drugs for colorectal cancer with Redeye and Isofol Medical

News / By

On April 10th, Redeye will organize an investor specialist event focusing on late-stage drugs aimed to treat colorectal cancer. Isofol Medical, along with Pledpharma, will present future development plans, upcoming milestones, pivotal study design and what obstacles remains in order be granted market authorisation. Moderating analysts will be Klas Palin and Arvid Necander. Link for …

Invitation to a specialist investor event focusing on late-stage drugs for colorectal cancer with Redeye and Isofol Medical Read More »

Scroll to Top